Amgen partnered with Micromet to develop BiTE antibodies against undisclosed solid tumor targets provided by Amgen

Micromet AG

Germany / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Amgen Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

$51,031.4m on 07/15/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced